TNF-alpha Inhibitor XTMAB-16 Granted FDA’s Orphan Drug Designation
News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to XTMAB-16, Xentria’s investigational TNF-alpha inhibitor for the treatment of sarcoidosis. The designation is given to candidate therapies ... Read more